Disease · MONDO_0019496
Comparisons in its trials17
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 17 of 17
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Octreotide, Bevacizumab vs Octreotide, Interferon Alpha-2b: serious adverse events | 68 of 197 | 9 of 194 | 391 | NCT00569127 | Trial comparisons |
| Lanreotide (Autogel Formulation) vs Placebo: serious adverse events | 25 of 101 | 32 of 103 | 204 | NCT00353496 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: deaths from any cause | 9 of 76 | 18 of 76 | 152 | NCT03365791 | Trial comparisons |
| PDR001+LAG525 On-treatment Period vs PDR001+LAG525 Extended Safety Follow-up Period: serious adverse events | 31 of 76 | 4 of 76 | 152 | NCT03365791 | Trial comparisons |
| Well-differentiated NET vs Poorly-differentiated GEP-NEC: PDR001 Anti-drug Antibodies (ADA) Prevalence at Baseline | 1 of 88 | 0 of 17 | 105 | NCT02955069 | Trial comparisons |
| Well-differentiated NET vs Poorly-differentiated GEP-NEC: PDR001 ADA Incidence On-treatment | 10 of 84 | 2 of 17 | 101 | NCT02955069 | Trial comparisons |
| Octreotide LAR (SMS995) vs Placebo: serious adverse events | 11 of 42 | 10 of 43 | 85 | NCT00171873 | Trial comparisons |
| Placebo + SSA vs Xermelo + SSA: deaths from any cause | 1 of 35 | 0 of 32 | 67 | NCT04810091 | Trial comparisons |
| Placebo + SSA vs Xermelo + SSA: serious adverse events | 3 of 35 | 4 of 32 | 67 | NCT04810091 | Trial comparisons |
| Carcinoid Tumor vs Islet Cell Carcinoma: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) | 31 of 31 | 12 of 12 | 43 | NCT00781911 | Trial comparisons |
| Carcinoid Tumor vs Islet Cell Carcinoma: serious adverse events | 12 of 31 | 6 of 12 | 43 | NCT00781911 | Trial comparisons |
| Sunitinib vs Everolimus: Number of Participants With Serious and Non-Serious Adverse Events | 15 of 15 | 11 of 11 | 26 | NCT02315625 | Trial comparisons |
| Sunitinib vs Everolimus: deaths from any cause | 1 of 15 | 1 of 11 | 26 | NCT02315625 | Trial comparisons |
| Sunitinib vs Everolimus: serious adverse events | 3 of 15 | 2 of 11 | 26 | NCT02315625 | Trial comparisons |
| Sunitinib First, Everolimus Second vs Everolimus First, Sunitinib Second: Number of Participants With an Overall Response | 1 of 14 | 0 of 2 | 16 | NCT02315625 | Trial comparisons |
| Group 1 - Dose Level 1 vs Group 1 - Dose Level 2: deaths from any cause | 7 of 9 | 0 of 2 | 11 | NCT02589522 | Trial comparisons |
| Group 1 - Dose Level 1 vs Group 1 - Dose Level 2: serious adverse events | 5 of 9 | 0 of 2 | 11 | NCT02589522 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019496/comparisons